Stay updated on Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Sign up to get notified when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.

Latest updates to the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision: v3.3.3 appears on the page, and 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' are removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedThe page history now lists Revision: v3.3.2, replacing v3.2.0. This appears to be a routine system release update rather than a change to study content or user-facing functionality.SummaryDifference0.1%

- Check45 days agoChange DetectedThe notice about government funding and potential delays was removed from the page. This banner previously informed users about data reliability and operating status.SummaryDifference0.4%

- Check60 days agoChange DetectedThe Record History page now shows additional recent versions with updated submission dates and status notes. The version history appears longer, reflecting ongoing updates to the study record.SummaryDifference0.1%

- Check81 days agoChange DetectedAdds current date (2025-10-10) and a new study status entry (2025-09-30), while removing an older date (2025-06-13. Overall, updates to time-sensitive content and status tracking.SummaryDifference0.8%

- Check88 days agoChange DetectedSummary: The page now displays a government-operating-status notice and announces a software version upgrade to v3.2.0, replacing the old v3.1.0.SummaryDifference9%

Stay in the know with updates to Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.